Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04691817 · ClinicalTrials.gov registry record · Phase 1

Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

A Phase 1 study of Lung Cancer, Nonsmall Cell, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
Phase 1
Development phase
28
Enrollment target
1
Study location

NCT04691817 is a Phase 1 study of Lung Cancer, Nonsmall Cell that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 28 participants, below the 789-participant average among 5 other Lung Cancer, Nonsmall Cell trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04691817, a Phase 1 study of Lung Cancer, Nonsmall Cell, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
Phase 1
Development phase
28 participants
Enrollment target
1
Study location

Study Summary

This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

Conditions Studied

Lung Cancer, Nonsmall Cell

Interventions

  • DRUG Atezolizumab
  • DRUG Tocilizumab

Study Locations (1)

Pennsylvania

  • Abramson Cancer Center of the University of Pennsylvania - Philadelphia

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2023-07-25
Est. Completion 2027-09
Phase Phase 1

Sponsor

Abramson Cancer Center at Penn Medicine

402 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04691817

The ClinicalTrials.gov registry entry for NCT04691817 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 789-participant average among 5 other Lung Cancer, Nonsmall Cell trials with a reported enrollment target (96% lower). The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Cancer, Nonsmall Cell appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.

NCT04691817 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04691817 about?

NCT04691817 is a clinical study titled "Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy". This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.

What is the current status of trial NCT04691817?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-07-25. Estimated completion is 2027-09.

What conditions does trial NCT04691817 study?

This clinical trial studies the following conditions: Lung Cancer, Nonsmall Cell.

What interventions are being tested in trial NCT04691817?

The interventions under investigation include: Atezolizumab (DRUG), Tocilizumab (DRUG).

Who is sponsoring clinical trial NCT04691817?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04691817 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer, Nonsmall Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer, Nonsmall Cell

All registered trials for this condition

Pennsylvania

All trials with a study site in Pennsylvania

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.